Current and future directions in theranostics for neuroendocrine prostate cancer

Gokce Belge Bilgin; Fabrice Lucien-Matteoni; Aadel A. Chaudhuri; Jacob J. Orme; Daniel S. Childs; Miguel Muniz; Gary G. Li; Pradeep S. Chauhan; Seung Baek Lee; Sounak Gupta; Matthew P. Thorpe; Derek R. Johnson; Geoffrey B. Johnson; Ayse Tuba Kendi; Oliver Sartor

doi:10.1016/j.ctrv.2025.102941

Current and future directions in theranostics for neuroendocrine prostate cancer

Gokce Belge Bilgin, Fabrice Lucien-Matteoni, Aadel A. Chaudhuri, Jacob J. Orme, Daniel S. Childs, Miguel Muniz, Gary G. Li, Pradeep S. Chauhan, Seung Baek Lee, Sounak Gupta, Matthew P. Thorpe, Derek R. Johnson, Geoffrey B. Johnson, Ayse Tuba Kendi, Oliver Sartor

Research output: Contribution to journal › Review article › peer-review

Abstract

Neuroendocrine prostate cancer (NEPC) is rare at the time of initial diagnosis but much more common in patients treated with the combination of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) such as abiraterone and enzalutamide. NEPC is typically characterized by the loss of prostate-specific membrane antigen (PSMA) expression while exhibiting variable neuroendocrine markers. Recent advancements in nuclear medicine have provided a promising avenue for the development of molecular imaging techniques and targeted therapies tailored to NEPC. This review examines the current and future role of theranostics in the diagnosis and management of NEPC and explores potential future directions in this rapidly evolving field.

Original language	English (US)
Article number	102941
Journal	Cancer Treatment Reviews
Volume	136
DOIs	https://doi.org/10.1016/j.ctrv.2025.102941
State	Published - May 2025

Keywords

Neuroendocrine prostate cancer
New targets
Theranostics

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctrv.2025.102941

Cite this

Belge Bilgin, G., Lucien-Matteoni, F., Chaudhuri, A. A., Orme, J. J., Childs, D. S., Muniz, M., Li, G. G., Chauhan, P. S., Lee, S. B., Gupta, S., Thorpe, M. P., Johnson, D. R., Johnson, G. B., Kendi, A. T., & Sartor, O. (2025). Current and future directions in theranostics for neuroendocrine prostate cancer. Cancer Treatment Reviews, 136, Article 102941. https://doi.org/10.1016/j.ctrv.2025.102941

@article{fdd0b0a6c9464472bfae1aecc9656bab,

title = "Current and future directions in theranostics for neuroendocrine prostate cancer",

abstract = "Neuroendocrine prostate cancer (NEPC) is rare at the time of initial diagnosis but much more common in patients treated with the combination of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) such as abiraterone and enzalutamide. NEPC is typically characterized by the loss of prostate-specific membrane antigen (PSMA) expression while exhibiting variable neuroendocrine markers. Recent advancements in nuclear medicine have provided a promising avenue for the development of molecular imaging techniques and targeted therapies tailored to NEPC. This review examines the current and future role of theranostics in the diagnosis and management of NEPC and explores potential future directions in this rapidly evolving field.",

keywords = "Neuroendocrine prostate cancer, New targets, Theranostics",

author = "\{Belge Bilgin\}, Gokce and Fabrice Lucien-Matteoni and Chaudhuri, \{Aadel A.\} and Orme, \{Jacob J.\} and Childs, \{Daniel S.\} and Miguel Muniz and Li, \{Gary G.\} and Chauhan, \{Pradeep S.\} and Lee, \{Seung Baek\} and Sounak Gupta and Thorpe, \{Matthew P.\} and Johnson, \{Derek R.\} and Johnson, \{Geoffrey B.\} and Kendi, \{Ayse Tuba\} and Oliver Sartor",

note = "Publisher Copyright: {\textcopyright} 2025",

year = "2025",

month = may,

doi = "10.1016/j.ctrv.2025.102941",

language = "English (US)",

volume = "136",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Current and future directions in theranostics for neuroendocrine prostate cancer

AU - Belge Bilgin, Gokce

AU - Lucien-Matteoni, Fabrice

AU - Chaudhuri, Aadel A.

AU - Orme, Jacob J.

AU - Childs, Daniel S.

AU - Muniz, Miguel

AU - Li, Gary G.

AU - Chauhan, Pradeep S.

AU - Lee, Seung Baek

AU - Gupta, Sounak

AU - Thorpe, Matthew P.

AU - Johnson, Derek R.

AU - Johnson, Geoffrey B.

AU - Kendi, Ayse Tuba

AU - Sartor, Oliver

PY - 2025/5

Y1 - 2025/5

N2 - Neuroendocrine prostate cancer (NEPC) is rare at the time of initial diagnosis but much more common in patients treated with the combination of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) such as abiraterone and enzalutamide. NEPC is typically characterized by the loss of prostate-specific membrane antigen (PSMA) expression while exhibiting variable neuroendocrine markers. Recent advancements in nuclear medicine have provided a promising avenue for the development of molecular imaging techniques and targeted therapies tailored to NEPC. This review examines the current and future role of theranostics in the diagnosis and management of NEPC and explores potential future directions in this rapidly evolving field.

AB - Neuroendocrine prostate cancer (NEPC) is rare at the time of initial diagnosis but much more common in patients treated with the combination of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) such as abiraterone and enzalutamide. NEPC is typically characterized by the loss of prostate-specific membrane antigen (PSMA) expression while exhibiting variable neuroendocrine markers. Recent advancements in nuclear medicine have provided a promising avenue for the development of molecular imaging techniques and targeted therapies tailored to NEPC. This review examines the current and future role of theranostics in the diagnosis and management of NEPC and explores potential future directions in this rapidly evolving field.

KW - Neuroendocrine prostate cancer

KW - New targets

KW - Theranostics

UR - https://www.scopus.com/pages/publications/105002577293

UR - https://www.scopus.com/inward/citedby.url?scp=105002577293&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2025.102941

DO - 10.1016/j.ctrv.2025.102941

M3 - Review article

AN - SCOPUS:105002577293

SN - 0305-7372

VL - 136

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

M1 - 102941

ER -

Current and future directions in theranostics for neuroendocrine prostate cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this